the vaccine – Communicable Diseases Research

Comparison of Wild Type DNA Sequence of Spike Protein from SARS-CoV-2 with Optimized Sequence on The Induction of Protective Responses Against SARS-Cov-2 Challenge in Mouse Model

마우스 모델에서 SARS-CoV-2 공격에 대한 보호 반응 유도에 대한 최적화된 서열과 SARS-CoV-2의 스파이크 단백질 야생형 DNA 서열의 비교

Article

Published on 2022-12-312022-09-11
Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 비임상, 진단,

[키워드] acid Against Antiviral binding breath CD4 CD8+ cellular immune responses cellular immunity challenge clinical trial contributing to COVID-19 CTL demonstrated DNA DNA vaccine expression full-length spike protein hACE2 humoral humoral and cellular immunity IFN-γ immune immune responses immunogen in vitro induction mice Model mouse Neutralizing antibodies optimization optimizations pGX-9501 platform Protective Protective effects protective response RBD binding response robust SARS-CoV-2 sequence spike Spike protein subsequent T cell T cells the vaccine Transgenic mouse Type virus wild-type wild-type sequence.
[DOI] 10.1080/21645515.2021.2016201 PMC 바로가기 [Article Type] Article

Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort study

Article

Published on 2022-12-012022-11-15
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술,

[키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant
[DOI] 10.1002/jmv.28055 PMC 바로가기

Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers

Article

Published on 2022-12-012022-11-15
Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 바이오마커, 변종, 진단,

[키워드] AstraZeneca Biomarker booster case-control study caused Chronic diseases Clinical severity conducted country COVID-19 COVID-19 confirmed patient COVID-19 patient COVID-19 vaccination COVID-19 vaccine CRP level Delta delta variant Delta wave dose doses effective Effectiveness Efficacy expressed females Health homologous Homologous vaccination hospital Hospitalization Hospitalized individual infected with SARS-CoV-2 Iraq Lower males molecular no significant difference no significant effect omicron Omicron variant pandemic Patient patients Pfizer Population Prevent recommendation recorded risk SARS-CoV-2 SARS-CoV-2 pandemic SARS-CoV-2 variant severity significantly Symptom the disease the vaccine transmissibility of SARS-CoV-2 vaccination Vaccine variant variants of concern virus VOCs was done WBC
[DOI] 10.1002/jmv.28098 PMC 바로가기

Immunogenicity and protectivity of intranasally delivered vector-based heterologous prime-boost COVID-19 vaccine Sputnik V in mice and non-human primates

Article

Published on 2022-12-012022-11-15
Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단,

[키워드] accompanied Blood clinical investigation Coverage COVID-19 COVID-19 pandemic COVID-19 vaccine cytokine release Diseases effective effort elicit Gam-COVID-Vac Health heterologous prime-boost IgA antibody IgG immune response Immunity immunization immunogenic immunogenicity Infection intranasal intranasal vaccine. intranasally K18-hACE2 transgenic mice less lung immunopathology mice mononuclear cell Mortality mucosal nasal mucosa neutralizing antibody non-human primate pandemic Peripheral blood Prevent proliferation protective immunity provided revaccination robust SARS-CoV-2 SARS-COV-2 infection SARSCoV-2 serum Sputnik V systemic and local the vaccine Transmission vaccination Vaccination strategy Vaccine vaccine candidate variants of concern virus virus infection virus spread
[DOI] 10.1080/22221751.2022.2119169 PMC 바로가기

Maternal SARS-CoV-2 sero-surveillance using newborn dried blood spot (DBS) screening specimens highlights extent of low vaccine uptake in pregnant women

Article

Published on 2022-11-302022-11-15
Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 변종, 진단,

Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study

Article

Published on 2022-11-302022-11-15
Journal: Human vaccines & immunotherapeutics [Category] COVID19(2023년), SARS, 진단,

Using host receptor as a decoy to treat COVID-19: a solution for immune escape?

Article

Published on 2022-11-082022-11-16
Journal: EMBO Molecular Medicine [Category] COVID19(2023년), SARS, 변종,

Viral load dynamics of SARS-CoV-2 Delta and Omicron variants following multiple vaccine doses and previous infection

Article

Published on 2022-11-072022-11-16
Journal: Nature Communications [Category] SARS, 변종,

Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age

Article

Published on 2022-11-032022-11-15
Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 변종, 진단,

[키워드] 95% CI 95% confidence interval acute respiratory syndrome Administered administration Adults Adverse age assigned authority B.1.1.529 children circulating Cohort cohorts coronavirus coronavirus disease criteria determine development dose duration of follow-up Efficacy elicited evaluate evaluated event geometric mean concentration immune response incidence Infection injection median Month mRNA-1273 mRNA-1273 vaccine neutralizing antibody observer-blinded open label Part phase 3 trial Placebo placebo-controlled predominant Randomly reactogenicity receive Safe Secondary objective selected the vaccine Trial Vaccine variant Year
[DOI] 10.1056/NEJMoa2209367 PMC 바로가기

Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases

Article

Published on 2022-11-022022-11-15
Journal: Rheumatology (Oxford, England) [Category] SARS, 진단, 치료기술,

[키워드] adverse event childhood-onset rheumatic disease Chinese Cohort COVID-19 COVID-19 infection cPass™ cut-off defined disease Disease activity dose Efficacy evaluate female first vaccination humoral immunogenicity immunogenicity increased the risk inhibition median medication Most patient mounted mRNA vaccination mRNA vaccine neutralization Neutralizing antibodies Neutralizing antibody response neutralizing response not affect Paediatric age paediatric rheumatology Patient positive predictor proportion remained response rheumatic disease SARS-CoV-2 SARS-CoV-2 vaccine second vaccination Serious Adverse Event serious complication Seven subgroup analysis symptomatic the SARS-CoV-2 the vaccine two-dose regimen vaccination Vaccine vaccine efficacy vaccine safety were assessed
[DOI] 10.1093/rheumatology/keac105 PMC 바로가기